APOPTOSIS INDUCING AGENTS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formulaor its therapeutically acceptable salts, wherein Arepresents furyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, thienyl, triazolyl, piperidinyl, morpholinyl, dihydro-1,3,4-thiadiazol-2-yl, benzothien-2-yl, banzothiazol-2-yl, tetrahydrothien-3-yl, [1,2,4]triazolo[1,5-a]pyrimidin-2-yl or imidazo[2,1-b][1,3]-thiazol-5-yl; wherein Ais unsubstituted or substituted by one, or two, or three, or four, or five substitutes independently specified in R, OR, C(O)OR, NHR, N(R), C(N)C(O)R, C(O)NHR, NHC(O)R, NRC(O)R, (O), NO, F, Cl, Br and CF; Rrepresents R, R, Ror R; Rrepresents phenyl; Rrepresents pyrazolyl or isoxazolyl; Rrepresents piperidinyl; Rrepresents C-Calkyl or C-Calkenyl each of which is not specified or specified by substitutes specified in R, SR, N(R), NHC(O)R, F and Cl; Rrepresents R, R, Ror R; Rrepresents phenyl; Rrepresents oxadiazolyl; Rrepresents morpholinyl, pyrrolidinyl or tetrahydropyranyl; Rrepresents C-Calkyl; Zrepresents phenylene; Zrepresents piperidine unsubstituted or substituted by OCH, or piperazine; both Zand Zare absent; Lrepresents C-Calkyl or C-Calkenyl each of which is unsubstituted or substituted by R; Rrepresents phenyl; Zrepresents Ror R; Rrepresents phenyl; Rrepresents cyclohexyl or cyclohexenyl; wherein phenylene presented by Zis unsubstituted or substituted by the group OR; Rrepresents Ror R; Rrepresents phenyl, which is uncondensed or condensed with pyrrolyl, imidazolyl or pyrazole; Rrepresents pyridinyl, which is uncondensed or condensed with pyrrolyl; wherein each cyclic fragment presented by R, R, R, R, R, R, R, R, Rand Ris independently unsubstituted or substituted by one or more substitutes independently specified in R, OR, C(O)OR, F, Cl CFand Br; Rrepresents Ror R; Rrepresents phenyl; Rrepresents C-Calkyl; and wherein phenyl presented by the group Ris unsubstituted or substituted by one or more substitutes independently specified in F and Cl.EFFECT: invention refers to a pharmaceutical composition containing the above compounds, and to a method of treating diseases involving the expression of anti-apoptotic Bcl-2 proteins.7 cl, 2 tbl, 48 ex Изобретение относится к соединению формулы I или его терапевтически приемлемым солям, где Апредставляет собой фурил, имидазолил, изотиазолил, изоксазолил, пиразолил, пирролил, тиазолил, тиадиазолил, тиенил, триазолил, пиперидинил, морфолинил, дигидро-1,3,4-тиадиазол-2